Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KAPA
stocks logo

KAPA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast KAPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAPA is 8.00 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast KAPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAPA is 8.00 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.909
sliders
Low
4.00
Averages
8.00
High
12.00
Current: 0.909
sliders
Low
4.00
Averages
8.00
High
12.00
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-04-17
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-04-17
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Initiates
$12
2025-04-03
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$12
2025-04-03
Initiates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-03-31
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-03-31
Maintains
Strong Buy
Reason
Maxim Group
Jason McCarthy
Strong Buy
Initiates
$4
2025-03-27
Reason
Maxim Group
Jason McCarthy
Price Target
$4
2025-03-27
Initiates
Strong Buy
Reason
Maxim analyst Jason McCarthy initiated coverage of Kairos Pharma with a Buy rating and $4 price target.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-03-20
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-03-20
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$9
2025-02-26
Reason
D. Boral Capital
Jason Kolbert
Price Target
$9
2025-02-26
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kairos Pharma Ltd (KAPA.A) is -3.50, compared to its 5-year average forward P/E of -4.90. For a more detailed relative valuation and DCF analysis to assess Kairos Pharma Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.90
Current PE
-3.50
Overvalued PE
-2.58
Undervalued PE
-7.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.52
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.04
Undervalued EV/EBITDA
-3.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

KAPA News & Events

Events Timeline

(ET)
2025-09-18
08:12:02
Kairos Pharma Reveals Interim Results of ENV105 Efficacy Analysis
select
2025-07-15 (ET)
2025-07-15
09:13:39
Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial
select
2025-03-31 (ET)
2025-03-31
07:07:24
Kairos Pharma completes safety lead-in of ENV105 trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-04Benzinga
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.

  • Market Winning Tools: Traders utilize Benzinga Pro's tools to gain a competitive edge and improve their trading success.

[object Object]
Preview
4.0
10-21NASDAQ.COM
D. Boral Capital Upholds Buy Rating for Kairos Pharma (KAPA)

  • Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for Kairos Pharma (NYSEAM:KAPA), with a projected one-year price target of $8.50/share, indicating a potential upside of 632.76% from its current price of $1.16/share.

  • Fund Sentiment and Ownership: There has been a 44.44% increase in the number of funds reporting positions in Kairos Pharma, although total shares owned by institutions decreased by 84.77% over the last three months, with notable holdings from firms like XTX Topco and Aptus Capital Advisors.

[object Object]
Preview
9.0
10-20Newsfilter
Kairos Pharma Discusses Phase 2 Trial Results of ENV-105 for Advanced Prostate Cancer at ESMO Conference

  • Interim Efficacy Analysis: Kairos Pharma's Phase 2 trial of ENV-105, a CD105 antagonist, shows promising results in treating metastatic castration-resistant prostate cancer, with 86% of patients benefiting from the combination therapy with apalutamide, and many remaining progression-free for over a year.

  • Clinical Trial Leadership: The trial, led by Dr. Edwin Posadas, is currently enrolling up to 100 patients across multiple cancer centers, aiming to demonstrate improved disease control and tolerability compared to existing treatments like chemotherapy and radioligand therapy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kairos Pharma Ltd (KAPA) stock price today?

The current price of KAPA is 0.9093 USD — it has increased 7.57 % in the last trading day.

arrow icon

What is Kairos Pharma Ltd (KAPA)'s business?

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.

arrow icon

What is the price predicton of KAPA Stock?

Wall Street analysts forecast KAPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAPA is 8.00 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kairos Pharma Ltd (KAPA)'s revenue for the last quarter?

Kairos Pharma Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Kairos Pharma Ltd (KAPA)'s earnings per share (EPS) for the last quarter?

Kairos Pharma Ltd. EPS for the last quarter amounts to -0.07 USD, decreased -30.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kairos Pharma Ltd (KAPA)'s fundamentals?

The market is revising No Change the revenue expectations for KAPA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -47.13%.
arrow icon

How many employees does Kairos Pharma Ltd (KAPA). have?

Kairos Pharma Ltd (KAPA) has 1 emplpoyees as of December 05 2025.

arrow icon

What is Kairos Pharma Ltd (KAPA) market cap?

Today KAPA has the market capitalization of 17.59M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free